Cargando…
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439172/ https://www.ncbi.nlm.nih.gov/pubmed/37596288 http://dx.doi.org/10.1038/s41523-023-00575-6 |
_version_ | 1785092885779054592 |
---|---|
author | Hopcroft, Lorna Wigmore, Eleanor M. Williamson, Stuart C. Ros, Susana Eberlein, Cath Moss, Jennifer I. Urosevic, Jelena Carnevalli, Larissa S. Talbot, Sara Bradshaw, Lauren Blaker, Catherine Gunda, Sreeharsha Owenson, Venetia Hoffmann, Scott Sutton, Daniel Jones, Stewart Goodwin, Richard J. A. Willis, Brandon S. Rooney, Claire DeBruin, Elza Barry, Simon T. |
author_facet | Hopcroft, Lorna Wigmore, Eleanor M. Williamson, Stuart C. Ros, Susana Eberlein, Cath Moss, Jennifer I. Urosevic, Jelena Carnevalli, Larissa S. Talbot, Sara Bradshaw, Lauren Blaker, Catherine Gunda, Sreeharsha Owenson, Venetia Hoffmann, Scott Sutton, Daniel Jones, Stewart Goodwin, Richard J. A. Willis, Brandon S. Rooney, Claire DeBruin, Elza Barry, Simon T. |
author_sort | Hopcroft, Lorna |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10439172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104391722023-08-20 Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models Hopcroft, Lorna Wigmore, Eleanor M. Williamson, Stuart C. Ros, Susana Eberlein, Cath Moss, Jennifer I. Urosevic, Jelena Carnevalli, Larissa S. Talbot, Sara Bradshaw, Lauren Blaker, Catherine Gunda, Sreeharsha Owenson, Venetia Hoffmann, Scott Sutton, Daniel Jones, Stewart Goodwin, Richard J. A. Willis, Brandon S. Rooney, Claire DeBruin, Elza Barry, Simon T. NPJ Breast Cancer Author Correction Nature Publishing Group UK 2023-08-18 /pmc/articles/PMC10439172/ /pubmed/37596288 http://dx.doi.org/10.1038/s41523-023-00575-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Author Correction Hopcroft, Lorna Wigmore, Eleanor M. Williamson, Stuart C. Ros, Susana Eberlein, Cath Moss, Jennifer I. Urosevic, Jelena Carnevalli, Larissa S. Talbot, Sara Bradshaw, Lauren Blaker, Catherine Gunda, Sreeharsha Owenson, Venetia Hoffmann, Scott Sutton, Daniel Jones, Stewart Goodwin, Richard J. A. Willis, Brandon S. Rooney, Claire DeBruin, Elza Barry, Simon T. Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models |
title | Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models |
title_full | Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models |
title_fullStr | Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models |
title_full_unstemmed | Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models |
title_short | Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models |
title_sort | author correction: combining the akt inhibitor capivasertib and serd fulvestrant is effective in palbociclib-resistant er+ breast cancer preclinical models |
topic | Author Correction |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439172/ https://www.ncbi.nlm.nih.gov/pubmed/37596288 http://dx.doi.org/10.1038/s41523-023-00575-6 |
work_keys_str_mv | AT hopcroftlorna authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT wigmoreeleanorm authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT williamsonstuartc authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT rossusana authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT eberleincath authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT mossjenniferi authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT urosevicjelena authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT carnevallilarissas authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT talbotsara authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT bradshawlauren authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT blakercatherine authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT gundasreeharsha authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT owensonvenetia authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT hoffmannscott authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT suttondaniel authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT jonesstewart authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT goodwinrichardja authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT willisbrandons authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT rooneyclaire authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT debruinelza authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels AT barrysimont authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels |